Chapter 1. General Introduction
|
|
- Stanley Blair
- 6 years ago
- Views:
Transcription
1 Chapter 1 General Introduction
2
3 Introduction Clostridium difficile is a Gram-positive, spore-forming, anaerobic bacterium that can act as a pathogen due to its ability to produce toxins. Toxin-producing C. difficile strains can merely colonise our bowels or cause gastrointestinal infection (C. difficile infection: CDI), with symptoms ranging from mild, selflimiting diarrhoea to severe pseudomembranous colitis and sepsis with high morbidity and mortality rates. CDI is a common and resilient cause of nosocomial diarrhoea. It is a major concern in hospitals and other healthcare facilities, since the spore-forming ability of C. difficile enhances transmission. Recurrence of CDI after an initial episode is common and adds further to the CDI related burden of morbidity and healthcare costs in a fragile, mostly elderly population. (1-3) Individual risk factors 1 Introduction The most important risk factor for developing C. difficile infection is use of antibiotics. C. difficile enters the body via the faeco-oral route when spores and vegetative cells are ingested. Spores can survive the acid environment of the stomach and germinate after arrival in the small bowel. Here vegetative C. difficile cells can colonise the intestines and under the right circumstances cause infection, e.g. when as a result of antibiotic exposure a niche in the disrupted microbiota allows proliferation. Practically all antibiotics have been associated with CDI, with clindamycin, fluoroquinolones, and cephalosporin imposing the highest risk. (1;4;5) There are several other factors that contribute to disturbed colonisation resistance : e.g. increasing age, extensive comorbidity or severe illness, abdominal surgery, chemotherapy and inflammatory bowel disease. (6) Other well described risk factors for CDI include hospitalisation (due to contamination of the environment, with carriage rates increasing over time), acquisition of specific C. difficile strains (especially the ribotype 027 strain), inadequate serum IgG antitoxin immune response and probably the use of gastric acid suppressors. (1;7;8) Morbidity, mortality and implications CDI has major implications for the individual patient and the healthcare system in general. Complications include severe pseudomembranous colitis (figure 1), toxic megacolon, perforation and sepsis, and death. After initial recovery, recurrent disease is common (on average 20-25% - but with large variation between 12% and 64% in observational studies) and recurrence risk increases with every episode. (9;10) Mortality has been investigated in various studies in a heterogeneous range of CDI populations, with varying definitions, sample size and quality estimating the attributable mortality at 6% of cases, again increasing with age. (9;11) Attributable costs are estimated at $3,000 - $30,000 per 13
4 Chapter 1 case of hospital-acquired CDI, mostly due to extended length of stay (3-21 days). (3) In the Netherlands approximately 3000 hospitalised patients develop CDI per year, of which an estimated 120 patients die. (12) Several infection control measures are recommended to minimise spread of spores within a hospital or healthcare facility, like protective clothing, hand hygiene, isolation precautions, environmental cleaning and cleaning of medical equipment, and good antibiotic stewardship. (13;14) Diagnosis Early and rapid identification of C. difficile infection is vital for the initiation of aforementioned infection control measures and treatment, and thus to limit transmission. (15) Diagnostic tests are aimed at demonstrating either the toxinproducing ( toxigenic ) bacterium itself, its antigens, its toxins or the genes coding for them. Numerous diagnostic tests are at hand. Figure 1: CT abdomen of a patient with severe pseudomembranous colitis due to C. difficile infection during the 2013 ribotype 027 outbreak in VU University medical centre. The colon is diffusely dilated with extensive bowel wall thickening. The patient underwent total colectomy, but died several days later of persistent septic shock and cardiac failure. 14
5 The traditional reference standard is the cell cytotoxicity assay (CCA). (16) For this test a mammalian cell culture is exposed to faecal eluate. The cell culture disintegrates due to cytotoxicity when C. difficile toxins are present in the stool sample, and the addition of antitoxin neutralizes the effects of the toxin on the cells (figure 2). (17;18) Because of the test s specialised requirements and turnaround time, most laboratories do not routinely use CCA anymore. Anaerobic culture on selective media, followed by testing cultured strains for the in vitro ability to produce toxins (toxigenic culture), is very sensitive and also referred to as a reference test, but is also time consuming. (17;18) Moreover, demonstrating the presence of toxigenic C. difficile strains in stool samples does not prove symptomatic infection since this also occurs in asymptomatic colonisation (limited specificity). In general, many clinical laboratories have moved to enzyme immunoassays (EIAs) detecting toxins or glutamate dehydrogenase (a cell-wall associated enzyme), and nucleic acid amplification tests (NAAT) because they are thought to be more cost-effective and offer turnaround times of minutes to hours instead of the 2 to 3 days required for CCA or toxigenic culture. Many of the EIAs are simple and easy to perform, but have limitations with regards to sensitivity and specificity. (17;18) Nucleic acid amplification tests to demonstrate genes coding for toxin production have high sensitivity and short turnaround time, but are more costly and require more specialised equipment and expertise. (17) Moreover, like culture alone, NAAT does not discriminate between infection and mere colonisation with a toxin producing C. difficile strain (limited specificity). Recent studies demonstrated the clinical relevance of this finding: patients with toxigenic C. difficile strains in their stool (as demonstrated by culture or NAAT) did not have an increased mortality unless there were toxins present in their stool. (19;20) This indicates presence of toxins in faecal samples best defines true C. difficile infection, or at least serious C. difficile infection, 1 Introduction Figure 2: Cell cytotoxicity assay (CCA) for the detection of C. difficile toxins A and B is performed upon mammalian cell cultures. Prepared faecal samples from suspected patients are added onto a monolayer of cultured cells (in this case Vero cell monolayers). Cells are inspected after 24 and 48 hours of incubation: the presence of toxins exert a cytopathic effect characterized by rounding of cells due to disruption of tight junctions and destruction of the cytoskeleton (right panel, 2b). Parallel samples that are incubated with specific C. difficile antitoxin do not show this effect (left panel, 2a). Source: dr. ir. J Corver and prof. dr. EJ Kuijper, Department of Medical Microbiology, Leiden University Medical Centre (LUMC), Netherlands. 15
6 Chapter 1 and the significance of only culture or NAAT positive samples is uncertain. Considering that the percentage of hospitalised patients asymptomatically colonised with C. difficile is up to 15-20% (6;8;21), and that diarrhoea due to non-cdi causes is common in this population, using only NAAT could cause substantial overdiagnosis and overtreatment. Molecular typing of C. difficile strains is important to gain a better understanding of the epidemiology of CDI, and specifically to identify outbreaks. Polymerase chain reaction (PCR) ribotyping is based on recognition of patterns of PCR products of the 16S-23S ribosomal ribonucleic acid (rrna) intergenic spacer region, and is the standard typing method used in Europe. C. difficile ribotype 027 appears to be mostly associated with severe disease, high recurrence rates and hospital outbreaks. Limited sensitivity and/or specificity of the current diagnostic options has led to the development of several diagnostic algorithms that combine tests to improve diagnostic accuracy. (17;18) First and foremost the diagnosis CDI should only be made in patients with symptoms suggestive of CDI, and not by laboratory findings alone. Clinicians should be aware that a substantial proportion of infected patients can be missed or overtreated based on standalone tests. The current guidelines therefore recommend combining tests to optimise positive and negative predictive value. (13;18) In daily practice, on top of the limitations of the available tests, several factors delay the identification of C. difficile infections. These include patient s and doctor s delay (e.g., the doctor does not consider the possibility of a C. difficile infection, or decides to wait and see if symptoms pass), delays in sampling stool, and time required to process samples in the laboratory. As a result, almost 3-8 days pass between onset of symptoms to start of treatment. (22;23) Treatment Considering that the disrupted gut microbiota plays a crucial role in CDI, discontinuing the causative antibiotic (if possible) is the most physiological treatment of CDI. In about 15% of (mild) cases cessation of the inciting antibiotic alone is sufficient to resolve symptoms. (17) For mild to moderate CDI, metronidazole is usually recommended as the first line antibiotic treatment, largely because of its efficacy, limited costs (a 10-day course costs about E7,- in the Netherlands (2016) (24) ), and extensive experience. (1;6;17;25;26) For the treatment of severe disease, vancomycin is better than metronidazole with regards to cure rates, but also significantly more expensive (E430,- for a course of 4 daily capsules of 250 mg; E80,- if the solution for infusion is taken orally in a dose of 4 x 125 mg (24) ); for milder cases vancomycin and metronidazole are considered equivalent. (27) Fidaxomicin has similar cure rates as vancomycin, but recurrence rates appear to be lower with fidaxomicin, especially for those not infected with ribotype 027. (28-30) A course of fidaxomicin currently costs over E 1700,- (24). Therefore, it is usually recommended to treat a first recurrence with the initial therapy (metronidazole or vancomycin), especially 16
7 in non-severe disease, although some guidelines favour vancomycin for all first recurrences. (1;6;17;25;26;31) For those with multiple recurrences, the efficacy of antibiotic treatment further decreases, which is not surprising considering antibiotics do nothing to restore gut microbiota. Immunotherapy (e.g. the use of monoclonal antitoxin antibodies or prophylactic immunisation) could reduce the recurrence rate of CDI; but is not yet available for routine clinical use. Faecal microbiota transfer (FMT), although still relatively unconventional, unappealing and unstandardized, seems to be by far the most effective treatment for recurrent CDI, with few short-term side effects. (29;32-37) 1 The scent of CDI In 2010 our nurses and medical staff were discussing the clinical patients admitted to the internal medicine ward of our hospital during the weekly grand rounds. It was reported that one of the patients had diarrhoea and on the suggestion whether it could be a C. difficile infection, an older nurse answered that she didn t think so it doesn t have that particular smell. Ever since the 1970s, when C. difficile was first identified as the cause of pseudomembranous colitis, the diarrhoea has often been described as having a characteristic smell. (38) Several studies were performed to determine the scent detection skills of nursing staff, and found large differences in their abilities. (39-41) Considering that dogs have a far superior sense of smell, we hypothesised it should be possible for the canine nose to detect CDI with better than human accuracy. Introduction Animal scent detection The use of animals as scent detectors is far from new. Since the early 18th century, monks living in the Swiss Alps kept Saint Bernard dogs to guide them on their rescue missions following bad snowstorms. The dogs were not trained by the monks, but younger dogs learned how to perform search missions from their elders. Similarly, dogs have been used for prey hunting for centuries. The traditional way of hunting for truffles is with the help of pigs and trained dogs alike. Other examples include Bedouins camels that use their sense of smell to find water by detecting geosmin (a bacterial product found in wet dirt) from up to 50 miles away, which is a real asset when travelling through the desert. Homing pigeons, used for pigeon post since before the time of Christ, are thought to at least partly depend on their sense of smell by navigating through odours they pick up from different wind directions. With regards to the medical field, our sense of smell has traditionally been one of our most readily available diagnostic tools. Well known examples are the smell of acetone in ketoacidotic patients in the emergency room, or of gas gangrene in wounds on the battle field. Chapter 2 gives an overview of use of scent in diagnosing disease. 17
8 Chapter 1 Early and rapid identification of CDI is important to prevent transmission by initiating adequate isolation measures and treatment. Studies have, however, shown that the mean time between the onset of symptoms and treatment is about 3-8 days. Despite the availability of a wide range of diagnostic tests, CDI is still a widespread healthcare-related infection. The potential of using a dog for detection is the possibility to screen hospital wards for infected patients. Such screening could overcome common delays in diagnosis and thus help to control and prevent CDI outbreaks. In Chapter 3 the results of a proof of principle study are presented, in which we trained a dog to detect C. difficile, both in stool samples and in infected patients on hospital wards. In Chapter 4 we assessed how accurate the trained detection dog was in identifying CDI patients in a real-life outbreak setting, rather than in a casecontrol pilot design. We wondered whether performing regular surveillance rounds of the hospital during this outbreak (like a pet scan ), could lead to earlier CDI detection compared to conventional diagnostic testing. Chapter 5 describes a case-control study of an outbreak caused by a ribotype 027 C. difficile strain: which hospital-associated factors drove the outbreak of this particular strain? In Chapter 6 we focus on olfactory detection by an electronic nose, i.e. profiling of volatile (organic) compounds (VOCs) in the headspace of faecal samples by means of Field Asymmetric Ion Mobility Spectrometry (FAIMS). FAIMS analyses the chemical composition of a gaseous mixture, for instance the VOCs emanating from a stool sample, based on how the molecules move through an oscillating electrical field. It creates a profile of the chemical composition of a sample (the chemical fingerprint ) rather than identifies individual components. Can FAIMS be used to distinguish C. difficile- positive from - negative stool samples? The FAIMS profile of gas-phase biomarkers emanating from stool samples mainly represents the gut microbiota. CDI patients with recurrent disease have more disturbed gut microbiota than those without. Chapter 7 describes whether FAIMS profiling can not only be used to diagnose C. difficile infection, but whether it can also predict recurrence risk by analysing the stool sample of the initial episode. Chapter 8 is the final part of the thesis, which contains the summary, general discussion and recommendations. 18
9 Reference List (1) Leffler DA, LaMont JT. Clostridium difficile infection. N Engl J Med 2015;372: (2) Evans CT, Safdar N. Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis 2015;60:S66-S71. (3) Gabriel L, Beriot-Mathiot A. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. J Hosp Infect 2014;88: (4) Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013;68: (5) Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69: (6) Keller JJ, Kuijper EJ. Treatment of recurrent and severe Clostridium difficile infection. Annu Rev Med 2015;66: (7) Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365: (8) Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342: (9) Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014;9:e (10) Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2015;36: (11) Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. J Infect 2010;61:1-8. (12) Dorp van SM, Harmanus C, Sanders IM, et al. Eighth annual report of the national reference laboratory for Clostridium difficile and results of the sentinel surveillance May May Center for Infectious Diseases Control (CLB), RIVM, Bilthoven. (13) Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31: (14) Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008;14:2-20. (15) Muto CA, Blank MK, Marsh JW, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive bundle approach. Clin Infect Dis 2007;45: (16) Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978;298: (17) Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015;313: (18) Crobach MJ, Planche T, Eckert C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016;22:S63-S81. (19) Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. Lancet Infect Dis 2013;13: (20) Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 2015;175: (21) Alasmari F, Seiler SM, Hink T, Burnham CA, Dubberke ER. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 2014;59: (22) Frenz MB, McIntyre AS. Reducing delays in the diagnosis and treatment of Clostridium difficile diarrhoea. QJM 2003;96: (23) Scheurer D. Diagnostic and treatment delays in recurrent Clostridium difficile-associated disease. J Hosp Med 2008;3: (24) Zorginstituut Nederland; (25) Bos JC, Schultsz C, van Gool T, Bauer MP, Prins JM. SWAB richtlijn antimicrobiële therapie voor acute infectieuze diarree. Optimaliseren van het antibioticabeleid in Nederland XVIII Introduction 19
10 Chapter 1 (26) Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108: (27) Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45: (28) Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12: (29) Nood van E, Keller JJ, Kuijper EJ, Speelman P. [New treatment options for infections with Clostridium difficile]. Ned Tijdschr Geneeskd 2013;157:A6580. (30) Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364: (31) Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20:1-26. (32) Youngster I, Sauk J, Pindar C, et al. Faecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014;58: (33) Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen faecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014;312: (34) Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh faecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016;315: (35) Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015;41: (36) Drekonja D, Reich J, Gezahegn S, et al. Faecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 2015;162: (37) Nood van E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor faeces for recurrent Clostridium difficile. N Engl J Med 2013;368: (38) Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46:S12-S18. (39) Burdette SD, Bernstein JM. Does the nose know? The odiferous diagnosis of Clostridium difficile-associated diarrhea. Clin Infect Dis 2007;44:1142. (40) Johansen A, Vasishta S, Edison P, Hosein I. Clostridium difficile associated diarrhoea: how good are nurses at identifying the disease? Age Ageing 2002;31: (41) Rao K, Berland D, Young C, Walk ST, Newton DW. The nose knows not: poor predictive value of stool sample odor for detection of Clostridium difficile. Clin Infect Dis 2013;56:
11
12
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationStony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
More informationLe infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo
Le infezioni da Clostridium difficile, gravi, ricorrenti e complicate Nicola Petrosillo Istituto Nazionale per le Malattie Infettive «lazzaro Spallanzani», IRCCS-Roma The infectious cycle of transmission
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationMarch 3, To: Hospitals, Long Term Care Facilities, and Local Health Departments
March 3, 2010 To: Hospitals, Long Term Care Facilities, and Local Health Departments From: NYSDOH Bureau of Healthcare Associated Infections HEALTH ADVISORY: GUIDANCE FOR PREVENTION AND CONTROL OF HEALTHCARE
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationClostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate
Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More informationModern approach to Clostridium Difficile Infection
Modern approach to Clostridium Difficile Infection Pseudomembranous Colitis: Principles for diagnosis and treatment Aggelos Stefos Internist, Infectious diseases Specialist Department of Medicine and Research
More informationFecal Microbiota Transplantation
Protocol Fecal Microbiota Transplantation (20192) Medical Benefit Effective Date: 10/01/14 Next Review Date: 07/18 Preauthorization Yes Review Dates: 07/14, 07/15, 07/16, 07/17 Preauthorization is required.
More informationDUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News. Volume 3, Number 6, June 2015
DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News Volume 3, Number 6, June 2015 Diagnostic Testing for Clostridium difficile Infection Background Clostridium difficile
More informationThe Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH
The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More informationClostridium difficile infection (CDI) Week 52 (Ending 30/12/2017)
Clostridium difficile infection (CDI) Week 52 (Ending 30/12/2017) What is Clostridium difficile? Clostridium difficile is a Gram-positive anaerobic spore forming bacillus. It is ubiquitous in nature and
More informationLong-Term Care Updates
Long-Term Care Updates April 2018 By Austin Smith, PharmD Candidate and Lindsay Slowiczek, PharmD is the most common healthcare-acquired infection (HAI) in the United States. 1,2 A 2014 prevalence survey
More informationACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Clostridium difficile Infections Christina M. Surawicz, MD 1, Lawrence J. Brandt, MD 2, David G. Binion, MD 3, Ashwin N. Ananthakrishnan,
More informationL infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici
L infezione da Clostridium difficile (CDI) Quadri clinici e nuovi approcci terapeutici Roberto Luzzati SC Malattie Infettive, AOU Trieste Presidente :Prof. Enzo Raise Clinical presentation of infection
More informationUpdate on Clostridium difficile infection.
Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-DE Medical Management Provider Notice Date: 10/15/2018; 04/15/2018 Issue Date: 11/15/2018;
More informationCase 1. Which of the following would be next appropriate investigation/s regarding the pts diarrhoea?
Case 1 21 yr old HIV +ve, Cd4-100 HAART naïve Profuse diarrhoea for 3/52. Stool MC&S ve Which of the following would be next appropriate investigation/s regarding the pts diarrhoea? Repeat stool MC&S Stool
More informationDoes Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
ISPUB.COM The Internet Journal of Infectious Diseases Volume 15 Number 1 Does Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
More informationClostridium difficile (C difficile)
Patient Knowledge and Attitudes About for Clostridium difficile Infection Colin Goodman, MD; Nicholas O Rourke, PharmD; Carla Amundson, MA; and Dimitri Drekonja, MD, MS In a survey of patients with Clostridium
More informationCorporate Medical Policy Fecal Microbiota Transplantation
Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Fecal Microbiota Transplant MP-066-MD-PA Medical Management Provider Notice Date: 10/15/2018; 01/15/2018 Issue Date: 11/15/2018;
More informationAnnex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening
Annex C: - CDI What s the diff? 4 th Annual Outbreak Management Workshop September 19, 2013 Naideen Bailey & Grace Volkening There s an updated Annex C Annex C is an extension to the PIDAC Infection Prevention
More informationClostridium difficile infection in an endemic setting in the Netherlands
Eur J Clin Microbiol Infect Dis (2011) 30:587 593 DOI 10.1007/s10096-010-1127-4 ARTICLE Clostridium difficile infection in an endemic setting in the Netherlands M. P. M. Hensgens & A. Goorhuis & C. M.
More informationNicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma. L infezione da C difficile grave o complicata
Nicola Petrosillo Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, IRCCS Roma L infezione da C difficile grave o complicata Bagdasarian N et al. JAMA 2015; 313: 398-408 European Society
More informationPros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection
Pros and Cons of Alternative Diagnostic Testing Strategies for C. difficile Infection Christopher R. Polage, MD, MAS Associate Professor of Pathology and Infectious Diseases UC Davis Disclosures Test materials
More informationLong-Term Care Updates
Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause
More informationL. Clifford McDonald, MD. Senior Advisor for Science and Integrity September 16, 2015
Controversies and Current Issues in Diagnosis, Surveillance, and Treatment of Clostridium difficile infeciton L. Clifford McDonald, MD Senior Advisor for Science and Integrity September 16, 2015 Division
More informationClostridium difficile in Children: To Treat or Not to Treat?
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2014.17.2.80 Pediatr Gastroenterol Hepatol Nutr 2014 June 17(2):80-84 Review Article PGHN Clostridium difficile in Children: To Treat or
More informationC. DIFF QUIK CHEK COMPLETE. Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE NEXT PAGE
C. DIFF QUIK CHEK COMPLETE Get the complete diagnostic picture with just one test. TAP HERE TO SEE THE PAGE CLINICIAN Would actionable C. difficile test results in less than 30 minutes improve patient
More informationDETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS DETECTION OF TOXIGENIC CLOSTRIDIUM DIFFICILE Policy Number: PDS 021 Effective Date:
More informationClostridium Difficile colitismore
Clostridium Difficile colitismore virulent than ever ECHO- February 18, 2016 Charles Krasner, M.D. UNR School of Medicine Sierra NV Veterans Affairs Hospital Growing problem of pseudomembranous colitis
More informationFecal transplantation as a treatment option for recurrent Clostridium difficile infection
Fecal transplantation as a treatment option for recurrent Clostridium difficile infection Josbert Keller Department of Gastroenterology Haga Teaching Hospital, The Hague Case: 81 yrs, CVA, recurrent UTI,
More informationESCMID Online Lecture Library. by author
ECDIS-NET: Update on Clostridium difficile epidemiology in Europe 1 E d J. K u i j p e r, S o f i e v a n D o r p a n d D a a n N o t e r m a n s. D e p a r t m e n t o f M e d i c a l M i c r o b i o
More informationFecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection
Fecal microbiota transplantation: Breaking the chain of recurrent C. difficile infection Issue Date: June 2013 Vol. 8 No. 6 Author: Amy Marinski, MSN, RN, CCRN, CNL More than 3 million new cases of Clostridium
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationClostridium Difficile Infection in Adults Treatment and Prevention
Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy
More informationClostridium difficile Infection (CDI) Guideline Update:
Clostridium difficile Infection (CDI) Guideline Update: Understanding the Data Behind the Recommendations Erik R. Dubberke, MD, MSPH A Webinar for HealthTrust Members Professor of Medicine September 24,
More informationSMT19969: A Selective Therapy for C. difficile Infection
SMT19969: A Selective Therapy for C. difficile Infection One Bug, One Drug 25 th September 2012 SMT19969: A Selective Therapy for CDI SMT19969 is a novel antibiotic for the specific treatment of Clostridium
More informationManaging Clostridium Difficile: An Old Bug With
932 The Red Section see related editorial on page x Managing Clostridium Difficile: An Old Bug With New Tricks Stephen M. Vindigni, MD, MPH 1,2 and Christina M. Surawicz, MD 1 Am J Gastroenterol (2018)
More informationFecal Microbiota Transplantation. Description
Section: Medicine Effective Date: April 15, 2017 Original Policy Date: September 12, 2014 Subject: Fecal Microbiota Transplantation Page: 1 of 10 Last Review Status/Date: March 2017 Fecal Microbiota Transplantation
More informationClostridium difficile: An Overview
Clostridium difficile: An Overview CDI Webinar July 11, 2017 PUBLIC HEALTH DIVISION Acute and Communicable Disease Prevention Section Outline Background Microbiology Burden Pathogenesis Diagnostic testing
More informationClostridium difficile infection surveillance: Applying the case definition
Clostridium difficile infection surveillance: Applying the case definition PICNet Conference March 3 rd 2016 Presented by: Tara Leigh Donovan, MSc Managing Consultant (Former Epidemiologist) 1 Disclaimer
More informationCDI The Impact. Disclosures. Acknowledgments. Objectives and Agenda. What s in the Name? 11/14/2012. Lets Talk Numbers
Disclosures No conflict of interest to declare Acknowledgments Objectives and Agenda Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Guidelines
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationClostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018
Clostridium difficile CRISTINA BAKER, MD, MPH INFECTIOUS DISEASE PARK NICOLLET/HEALTH PARTNERS 11/9/2018 Disclosures None Objectives Highlight important changes in the management of Clostridium difficile
More informationThe Bristol Stool Scale and Its Relationship to Clostridium difficile Infection
JCM Accepts, published online ahead of print on 16 July 2014 J. Clin. Microbiol. doi:10.1128/jcm.01303-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 The Bristol Stool Scale
More informationCLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT. Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates
CLOSTRIDIUM DIFFICILE: IMPROVING DIAGNOSIS AND TREATMENT Joshua T. Watson, M.D. Lowcountry Gastroenterology Associates Learning Objectives Recognize patients who are highest risk for C. diff infections
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationClostridioides difficile Infection: What s the BIG Stink?
Clostridioides difficile Infection: What s the BIG Stink? GLORIA MATHIS, RN, BSN, CIC 29 TH ANNUAL MEDICAL SURGICAL CONFERENCE APRIL 4, 2019 SAN FRANCISCO, CA I am sre my patient has C. diff. I cold smell
More information6/14/2012. Welcome! PRESENTATION OUTLINE CLOSTRIDIUM DIFFICILE PREVENTION. Teaming Up to Prevent Infections! 1) Impact. 2) Testing Recommendations
CLOSTRIDIUM DIFFICILE PREVENTION Beth Goodall, RN, BSN Board Certified in Infection Prevention and Control DCH Health System Epidemiology Director Welcome! Teaming Up to Prevent Infections! CLOSTRIDIUM
More informationQuestions and answers about the laboratory diagnosis of Clostridium difficile infection (CDI)
Questions and answers about the laboratory diagnosis of Clostridium difficile infection (CDI) The NHS Centre for Evidence based Purchasing (CEP) has published the results of an evaluation of the performance
More informationStar Articles in Review
Star Articles in Review CDDW/CASL Meeting Toronto, February 10, 2014 Christina M. Surawicz, MD MACG Professor of Medicine Division of Gastroenterology Department of Medicine University of Washington Disclosure
More informationClostridium difficile
Clostridium difficile Care Homes IPC Study Day Sue Barber Infection Prevention & Control Lead AV & Chiltern CCG s Clostridium difficile A spore forming Bacterium. Difficult to grow in the laboratory hence
More informationLiterature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Policy Title: Fecal transplantation for clostridium difficile infection
Clinical Policy Title: Fecal transplantation for clostridium difficile infection Clinical policy number: 08.02.02 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date:
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationClinical Infectious Diseases Advance Access published December 7, 2012
Clinical Infectious Diseases Advance Access published December 7, 2012 1 Physician Attitudes Towards the Use of Fecal Transplantation for Recurrent Clostridium Difficile Infection in a Large Metropolitan
More informationIncidence of and risk factors for communityassociated Clostridium difficile infection
University of Iowa Iowa Research Online Theses and Dissertations 2010 Incidence of and risk factors for communityassociated Clostridium difficile infection Jennifer Lee Kuntz University of Iowa Copyright
More informationLearning Goals. Clostridium difficile. Historical Context. Historical Context 6/27/2012
Learning Goals Clostridium difficile Justin L. Sewell, MD, MPH Assistant Clinical Professor of Medicine University of California San Francisco San Francisco General Hospital Understand the epidemiology,
More informationClostridium difficile Diagnostic and Clinical Challenges
Papers in Press. Published December 11, 2015 as doi:10.1373/clinchem.2015.243717 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2015.243717 Clinical Chemistry 62:2 000 000
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationClinical Policy Bulletin: Fecal Bacteriotherapy
Clinical Policy Bulletin: Fecal Bacteriotherapy Number: 0844 Policy Aetna considers fecal bacteriotherapy medically necessary for persons with Clostridium difficile infection, with infection confirmed
More informationmore intense treatments are needed to get rid of the infection.
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting
More informationClostridium difficile Infection (CDI)
18.09.10 월요집담회 Clostridium difficile Infection (CDI) R4 송주혜 Clostridium difficile infection (CDI) Anaerobic gram (+), spore-forming, toxin(tcda&tcdb)-producing bacillus Transmitted among humans through
More informationClostridium Difficile Associated Disease. Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011
Clostridium Difficile Associated Disease Edmund Krasinski, Jr., D.O., F.A.C.G. Southwest Conference on Medicine 2011 Introduction Which of the following is more common in community hospitals in the Southeast
More informationFecal Microbiota Transplantation
Fecal Microbiota Transplantation Policy Number: 2.01.92 Last Review: 7/2018 Origination: 5/2015 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationThe incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment.
C. DIFFICILE Case definition CONFIRMED CASE A patient is defined as a case if they are one year of age or older AND have one of the following requirements: A laboratory confirmation of a positive toxin
More informationClostridium difficile: Can you smell the new updates?
Clostridium difficile: Can you smell the new updates? Sunish Shah, Pharm.D. PGY-2 Infectious Disease Pharmacy Resident Yale-New Haven Hospital sshah1741@mail.usciences.edu Learning objectives Recognize
More informationWhat s New for Clostridium difficile John Lynch MD MPH Harborview Medical Center University of Washington
What s New for Clostridium difficile 2013 John Lynch MD MPH Harborview Medical Center University of Washington Pathogenic Mechanisms of Diarrhea Toxins: Preformed: S aureus, C perfringens, B cereus Formed
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationAll POOPed out: fecal microbiota transplant in C. difficile
All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL
More informationAntibiotic treatment comparison in patients with diarrhea
Original Research Article Antibiotic treatment comparison in patients with diarrhea Deva Lal Kast * Senior Consultant Physician, Department of General Medicine, Krishna Hospital, Ex senior Specialist and
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More informationClostridium difficile Essential information
Clostridium difficile Essential information Clostridium difficile Origins Clostridium difficile (C. diff) is a Gram positive, spore forming, anaerobic bacterium with a rod structure. It was first identified
More informationAccepted Article. Fecal microbiota transplantation - something more than merely a therapeutic curiosity
Accepted Article Fecal microbiota transplantation - something more than merely a therapeutic curiosity CARLOS FERRE ARACIL, Lara Aguilera Castro, Enrique Rodriguez de Santiago, Ana García García de Paredes,
More informationMAJOR ARTICLE. Clostridium difficile infection; vancomycin; metronidazole; mortality; sepsis.
MAJOR ARTICLE The Addition of Intravenous Metronidazole to Oral Vancomycin is Associated With Improved Mortality in Critically Ill Patients With Clostridium difficile Infection Kristina E. E. Rokas, 1
More informationCan We Prevent All Healthcare- Associated Clostridium difficile infections in 10 Years?
Can We Prevent All Healthcare- Associated Clostridium difficile infections in 10 Years? Curtis Donskey, M.D. Louis Stokes VA Medical Center Cleveland, Ohio Research support: Clorox, EcoLab, GOJO, Merck,
More informationLos Angeles County Department of Public Health: Your Partner in CDI Prevention
Los Angeles County Department of Public Health: Your Partner in CDI Prevention Dawn Terashita, MD, MPH Acute Communicable Disease Control Los Angeles County Department of Public Health dterashita@ph.lacounty.gov
More informationHistorical Perspective
The Diagnosis of C. difficile Infections: Does Molecular Make it More or Less difficile? Stephen M. Brecher Ph.D. VA Boston Health Care System BU School of Medicine The opinions expressed in this presentation
More informationClinical. Clostridium Difficile: Standard Operating Procedure. Document Control Summary. Contents
Clinical Clostridium Difficile: Standard Operating Procedure Document Control Summary Status: Version: Author/Title: Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation
More informationLaboratory diagnosis of Clostridium difficile infection
Review Article Page 1 of 5 Laboratory diagnosis of Clostridium difficile infection Katherine Kendrick Mercer University School of Medicine (SOM), Navicent Health, Macon, GA, USA Correspondence to: Katherine
More informationBezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile. Janel Liane Cala, RPh Medical Center Hospital
Bezlotoxumab (Zinplava) as Adjunct Treatment for Clostridium difficile Janel Liane Cala, RPh Medical Center Hospital Objectives Review pathophysiology, risk factors, prevention, and treatment options of
More informationFecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond
Fecal Microbiota Transplantation (FMT): Current Concepts in Clostridium difficile and beyond Amir Patel, MD Assistant Professor of Medicine Froedtert Hospital and the Medical College of Wisconsin I have
More informationTerapia dell infezione da Clostridium difficile. Massimo Coen I Div Mal Inf AO L Sacco
Terapia dell infezione da Clostridium difficile Massimo Coen I Div Mal Inf AO L Sacco Disease Severity Mild CDI 3 5 BM/day WBC 15,000/mm 3 Defining CDI Disease Severity Mild abdominal pain due to CDI Moderate
More informationClostridiodes Difficile Colitis: Update on Guidelines. Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018
Clostridiodes Difficile Colitis: Update on Guidelines Jade Le, MD Texas Health Physicians Group No disclosures April 6, 2018 Outline Overview of CDI Diagnosis of C Difficile- updates Infection Prevention
More informationFaecal Microbiota Transplants: The evidence and experience
Faecal Microbiota Transplants: The evidence and experience Dr Simon Goldenberg Consultant Microbiologist and Infection Control Doctor Guy s & St Thomas NHS Foundation Trust Gut microbiota and health Level
More informationThe Epidemiology of Clostridium difficile Infection in Children: A Population-Based Study
Clinical Infectious Diseases Advance Access published March 5, 2013 MAJOR ARTICLE The Epidemiology of Clostridium difficile Infection in Children: A Population-Based Study Sahil Khanna, 1 Larry M. Baddour,
More informationC lostridium difficile is an anaerobic Gram positive bacillus
673 GASTROINTESTINAL INFECTION Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of S S Johal, J Hammond, K Solomon, P D James, Y R Mahida...
More informationNew approaches to treating Clostridium difficile Infection
7:45 8:45 am New Approaches to Treating C. difficile Infection SPEAKER Fred A. Lopez, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Fred A. Lopez,
More informationIdentification of Factors Impacting Recurrent Clostridium difficile Infection and Development of a Risk Evaluation Tool
Identification of Factors Impacting Recurrent Clostridium difficile Infection and Development of a Risk Evaluation Tool Bethanne P Carpenter 1, Erin K Hennessey 2,3, Alex M Bryant 3, Jad A Khoury 3, Andrew
More informationOvercoming barriers to effective recognition and diagnosis of Clostridium difficile infection
REVIEW 10.1111/1469-0691.12057 Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection M. H. Wilcox Department of Microbiology, Old Medical School, Leeds Teaching
More information